Erratum: Gene of the month: MET (J Clin Pathol (2015) 68 (405-409) DOI: 10.1136/jclinpath-2015-203050);Gene of the month: MET

Journal of Clinical Pathology

Volumn 68, Issue 6, 2015, Pages 405-409

  Skead, Garret ^a   Govender, Dhirendra ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

SCATTER FACTOR; SCATTER FACTOR RECEPTOR; MET PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR;

ARTICLE; BLADDER CARCINOMA; BREAST CARCINOMA; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CELL STRUCTURE; CELL SURVIVAL; DISEASE ASSOCIATION; EMBRYO DEVELOPMENT; GASTROINTESTINAL CARCINOMA; GENE ACTIVATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; HEAD AND NECK CARCINOMA; HUMAN; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG CARCINOMA; NONHUMAN; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; GENETICS; GERMLINE MUTATION; MISSENSE MUTATION; NEOPLASMS;

GERM-LINE MUTATION; HEPATOCYTE GROWTH FACTOR; HUMANS; MUTATION, MISSENSE; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MET; SIGNAL TRANSDUCTION;

EID: 84929624111     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2015-203050     Document Type: Erratum

References (35)

1. Liu Y. The human hepatocyte growth factor receptor gene: complete structural organization and promoter characterization. Gene 1998;215:159-69.
2. Gherardi E, Birchmeier W, Birchmeier C, et al. Targeting MET in cancer: rationale and progress. Nat Rev Cancer 2012;12:89-103.
3. Holmes O, Pillozzi S, Deakin J, et al. Insights into the structure/function of hepatocyte growth factor/scatter factor from studies with individual domains. J Mol Biol 2007;367:395-408.
4. Stamos J, Lazarus R, Yao X, et al. Crystal structure of the HGF beta-chain in complex with the Sema domain of the Met receptor. EMBO J 2004;23:2325-35.
5. Maina F, Casagranda F, Auder E, et al. Uncoupling of GRb2 from the Met receptor in vivo reveals complex roles in muscle development. Cell 1996;87:531-42.
6. Ponzetto C, Bardelli A, Zhen Z, et al. A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell 1994;77:261-71.
7. Sachs M, Weidner K, Brinkmann V, et al. Motogenic and morphogenic activity of epithelial receptor tyrosine kinases. J Cell Biol 1996;133:1095-107.
8. Birchmeier C, Birchmeier W, Gherardi E, et al. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003;4:915-25.
9. Furge KA, Zhang Y-W, Vande WG. Met receptor tyrosine kinase: enhanced signaling through adapter proteins. Oncogene 2000;19:5582-9.
10. Organ SL, Tsao M-S. An overview of the c-MET signaling pathway. Ther Adv Med Oncol 2011;3(1 suppl):S7-19.
11. Zhang YW, Vande Woude GF. HGF/SF-met signaling in the control of branching morphogenesis and invasion. J Cell Biochem 2003;88:408-17.
12. Delitto D, Vertes-George E, Hughes SJ, et al. c-Met signaling in the development of tumorigenesis and chemoresistance: potential applications in pancreatic cancer. World J Gastroenterol 2014;20:8458-70.
13. Stoker M, Gherardi E, Perryman M, et al. Scatter factor is a fibroblast-derived modulator of epithelial cell mobility. Nature 1987;327:239-42.
14. Stefan M, Koch A, Mancini A, et al. Src homology 2-containing inositol 5-phosphatase 1 binds to the multifunctional docking site of c-Met and potentiates hepatocyte growth factor-induced branching tubulogenesis. J Biol Chem 2001;276:3017-23.
15. Gelsomino F, Rossi G, Tiseo M. MET and small-cell lung cancer. Cancers 2014;6:2100-15.
16. Kawaguchi M, Kataoka H. Mechanisms of hepatocyte growth factor activation in cancer tissues. Cancers 2014;6:1890-904.
17. Abounader R, Reznik T, Colantuoni C, et al. Regulation of c-Met-dependent gene expression by PTEN. Oncogene 2004;23:9173-82.
18. Bladt F, Riethmacher D, Isenmann S, et al. Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud. Nature 1995;376:768-71.
19. Bozzuto G, Ruggieri P, Molinari A. Molecular aspects of tumor cell migration and invasion. Ann Ist Super Sanita 2010;46:66-80.
20. Hack SP, Bruey JM, Koeppen H. HGF/MET-directed therapeutics in gastroesophageal cancer: a review of clinical and biomarker development. Oncotarget 2014;5:2866-80.
21. Smyth EC, Sclafani F, Cunningham D. Emerging molecular targets in oncology: clinical potential of MET/hepatocyte growth-factor inhibitors. Onco Targets Ther 2014;7:1001-14.
22. Scagliotti GV, Novello S, Von Pawel J. The emerging role of MET/HGF inhibitors in oncology. Cancer Treat Rev 2013;39:793-801.
23. Cooper CS, Park M, Blair DG, et al. Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature 1984;311:29-33.
24. Haas NB, Nathanson KL. Hereditary kidney cancer syndromes. Adv Chronic Kidney Dis 2014;21:81-90.
25. Pennacchietti S, Michieli P, Galluzzo M, et al. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 2003;3:347-61.
26. Maulik G, Shrikhande A, Kijima T, et al. Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. Cytokine Growth Factor Rev 2002;13:41-59.
27. Kuonen F, Secondini C, Rüegg C. Molecular pathways: emerging pathways mediating growth, invasion, and metastasis of tumors progressing in an irradiated microenvironment. Clin Cancer Res 2012;18:5196-202.
28. Harshman LC, Choueiri TK. Targeting the hepatocyte growth factor/c-Met signaling pathway in renal cell carcinoma. Cancer J 2013;19:316-23.
29. Cecchi F, Rabe DC, Bottaro DP. Targeting the HGF/Met signaling pathway in cancer therapy. Expert Opin Ther Targets 2012;16:553-72.
30. Yano S, Nakagawa T. The current state of molecularly targeted drugs targeting HGF/Met. Jpn J Clin Oncol 2014;44:9-12.
31. Yan B, Lim M, Zhou L, et al. Identification of MET genomic amplification, protein expression and alternative splice isoforms in neuroblastomas. Journal of Clinical Pathology 2013;66:985-91.
32. Gridelli C, Peters S, Sgambato A, et al. ALK inhibitors in the treatment of advanced NSCLC. Cancer Treat Rev 2014;40:300-6.
33. Qi J, McTigue MA, Rogers A, et al. Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors. Cancer Res 2011;71:1081-91.
34. Iveson T, Donehower RC, Davidenko I, et al. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study. Lancet Oncol 2014;15:1007-18.
35. Grullich C. Cabozantinib: a MET, RET, and VEGFR2 tyrosine kinase inhibitor. Recent Results Cancer Res 2014;201:207-14.